DE69434752D1 - Opioid-Formulierungen zur Schmerzbehandlung - Google Patents

Opioid-Formulierungen zur Schmerzbehandlung

Info

Publication number
DE69434752D1
DE69434752D1 DE69434752T DE69434752T DE69434752D1 DE 69434752 D1 DE69434752 D1 DE 69434752D1 DE 69434752 T DE69434752 T DE 69434752T DE 69434752 T DE69434752 T DE 69434752T DE 69434752 D1 DE69434752 D1 DE 69434752D1
Authority
DE
Germany
Prior art keywords
dose
opioid analgesic
opioid
formulation
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434752T
Other languages
English (en)
Other versions
DE69434752T2 (de
Inventor
Richard Sackler
Paul Goldenheim
Robert Kaiko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22559696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69434752(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of DE69434752D1 publication Critical patent/DE69434752D1/de
Application granted granted Critical
Publication of DE69434752T2 publication Critical patent/DE69434752T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
DE69434752T 1993-11-23 1994-11-22 Opioid-Formulierungen zur Schmerzbehandlung Expired - Lifetime DE69434752T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US156468 1993-11-23
US08/156,468 US5478577A (en) 1993-11-23 1993-11-23 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level

Publications (2)

Publication Number Publication Date
DE69434752D1 true DE69434752D1 (de) 2006-07-06
DE69434752T2 DE69434752T2 (de) 2007-05-16

Family

ID=22559696

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69429826T Expired - Lifetime DE69429826T3 (de) 1993-11-23 1994-11-22 Opioid-formulierungen zur schmerzbehandlung
DE69434752T Expired - Lifetime DE69434752T2 (de) 1993-11-23 1994-11-22 Opioid-Formulierungen zur Schmerzbehandlung
DE69434911T Expired - Lifetime DE69434911T2 (de) 1993-11-23 1994-11-22 Opioid-Formulierungen zur Schmerzbehandlung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69429826T Expired - Lifetime DE69429826T3 (de) 1993-11-23 1994-11-22 Opioid-formulierungen zur schmerzbehandlung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69434911T Expired - Lifetime DE69434911T2 (de) 1993-11-23 1994-11-22 Opioid-Formulierungen zur Schmerzbehandlung

Country Status (23)

Country Link
US (10) US5478577A (de)
EP (4) EP1023896B1 (de)
JP (5) JPH09505602A (de)
KR (1) KR100201767B1 (de)
CN (1) CN1134253C (de)
AT (3) ATE212831T1 (de)
AU (1) AU693134B2 (de)
BG (1) BG63269B1 (de)
CZ (1) CZ292936B6 (de)
DE (3) DE69429826T3 (de)
DK (3) DK1470815T3 (de)
ES (3) ES2279742T3 (de)
FI (1) FI121588B (de)
HK (1) HK1029927A1 (de)
HU (1) HUT73976A (de)
IL (1) IL111742A (de)
NO (1) NO315147B1 (de)
NZ (3) NZ336055A (de)
PL (1) PL312587A1 (de)
PT (3) PT1470815E (de)
SK (1) SK283544B6 (de)
TW (1) TW420617B (de)
WO (1) WO1995014460A1 (de)

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460972A (en) * 1991-04-08 1995-10-24 Research Foundation Of The State University Of New York Ionized magnesium2+ concentrations in biological samples
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
DE59305805D1 (de) * 1992-10-26 1997-04-17 Goedecke Ag Tilidin-dihydrogenorthophosphat, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
SE9301057L (sv) † 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) * 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
EP0672416A1 (de) * 1994-03-14 1995-09-20 Euro-Celtique S.A. Diamorphin enthaltendes Arzneimittel
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US7060293B1 (en) 1994-05-25 2006-06-13 Purdue Pharma Powder-layered oral dosage forms
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
DE69618956T2 (de) * 1995-06-09 2002-08-22 Scherer Technologies Inc R P Weichgelatinekapsel mit teilchenmaterial
GB9519363D0 (en) * 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
CA2238815A1 (en) * 1995-12-07 1997-06-12 Charles Howard Mitch Composition for treating pain
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
PL188919B1 (pl) * 1996-03-08 2005-05-31 Nycomed Danmark As Doustna, multijednostkowa kompozycja preparatu farmaceutycznego o modyfikowanym uwalnianiu oraz sposób wytwarzania jednostki dawkowania doustnej multijednostkowej kompozycji farmaceutycznej o modyfikowanym uwalnianiu
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
BE1010803A3 (fr) * 1996-12-16 1999-02-02 Therabel Research Sa Comprimes pharmaceutiques a liberation prolongee a base de tramadol et leur preparation.
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
WO1999001111A1 (en) * 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
EP1017370B1 (de) * 1997-09-11 2003-10-29 Nycomed Danmark ApS Aus mehreren einzeleinheiten zusammengesetzte arzneimittel mit nicht-steroidalen wirkstoffen (nsaids)
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
TW477702B (en) 1997-10-23 2002-03-01 Dev Center Biotechnology Controlled release tacrine dosage form
ES2415876T3 (es) 1997-12-22 2013-07-29 Euro-Celtique S.A. Forma de dosificación farmacéutica oral que comprende una combinación de un agonista de opiáceos y un antagonista de opiáceos
EP0928610A1 (de) * 1998-01-08 1999-07-14 Development Center For Biotechnology Tacrine enthaltende Dosierungsform zur kontrollierten Freigabe
FR2774910B1 (fr) * 1998-02-16 2001-09-07 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques
JP2002504505A (ja) * 1998-02-25 2002-02-12 アボット・ラボラトリーズ ブトルファノール持続放出性製剤
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
CA2327685C (en) * 1998-04-03 2008-11-18 Bm Research A/S Controlled release composition
CO5070568A1 (es) 1998-05-22 2001-08-28 Eurand Internatrional Spa Proceso de aplicacion de capas y aparato para efectuarlo
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
FR2794646B1 (fr) * 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
DE60015370T2 (de) * 1999-08-27 2006-03-09 Southern Research Institute, Birmingham Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum
CA2388560A1 (en) * 1999-08-31 2001-03-08 Grunenthal Gmbh Sustained-release form of administration containing tramadol saccharinate
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
IL149352A0 (en) * 1999-10-29 2002-11-10 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) * 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN101703777B (zh) 2000-02-08 2012-11-28 欧罗赛铁克股份有限公司 抗破坏口服阿片样激动剂
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
US7858118B2 (en) * 2001-04-11 2010-12-28 Galephar Pharmaceutical Research, Inc. Extended release composition containing Tramadol
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
EP1387673B1 (de) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Opioid enthaltende arzneiform gegen missbrauch
US20030064122A1 (en) * 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
US9820982B2 (en) 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20030129234A1 (en) * 2001-07-06 2003-07-10 Penwest Pharmaceuticals Company Methods of making sustained release formulations of oxymorphone
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
PT1416842E (pt) 2001-07-18 2009-03-31 Euro Celtique Sa Composições farmacêuticas de oxicodona e naloxona
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
KR20040029405A (ko) 2001-08-06 2004-04-06 유로-셀티크 소시에떼 아노뉨 방출성 및 격리된 길항제와 오피오이드 효능제의 제제
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
EP1429728A1 (de) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Zubereitungen mit verzögerter freisetzung
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (de) 2001-09-21 2015-12-23 Egalet Ltd. Polymer-freigabe-system
US7854230B2 (en) * 2001-10-22 2010-12-21 O.R. Solutions, Inc. Heated medical instrument stand with surgical drape and method of detecting fluid and leaks in the stand tray
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
RU2311903C2 (ru) * 2001-11-07 2007-12-10 Синтон Б.В. Таблетки тамзулосина
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US8128957B1 (en) * 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
EP3241548A1 (de) 2002-04-05 2017-11-08 Euro-Celtique S.A. Matrix für nachhaltige, invariante und unabhängige freisetzung von wirkstoffverbindungen
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
AU2003234216A1 (en) * 2002-04-29 2003-11-17 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
DK2561860T3 (en) 2002-05-31 2018-04-30 Titan Pharmaceuticals Inc Implantable polymer device for prolonged release of buprenorphine
AU2003245345A1 (en) * 2002-05-31 2003-12-19 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
WO2004026256A2 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
WO2004026262A2 (en) * 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
ES2350689T3 (es) * 2002-12-13 2011-01-26 Durect Corporation Sistema de suministro de fármacos oral que comprende materiales vehículo líquidos de alta viscosidad.
DE10300325A1 (de) 2003-01-09 2004-07-22 Hexal Ag Granulat mit öliger Substanz, Herstellungsverfahren und Tablette
US7648982B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7648981B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
EP1905435A3 (de) * 2003-03-11 2008-05-14 Euro-Celtique S.A. Titrationsdosierschema zur kontrollierten Abgabe von Tramadol
JP4989217B2 (ja) * 2003-03-26 2012-08-01 エガレット エイ／エス 薬剤物質の送達制御用マトリックス組成物
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
NZ542548A (en) 2003-03-31 2009-04-30 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
MXPA05011071A (es) 2003-04-21 2005-12-12 Euro Celtique Sa Forma de dosificacion resistente a la alteracion que comprende particulas co-extrusionadas de agente adverso y proceso de fabricacion de las misma.
US20050089570A1 (en) * 2003-09-26 2005-04-28 Evangeline Cruz Oros push-stick for controlled delivery of active agents
KR101169614B1 (ko) * 2003-09-26 2012-08-03 알자 코포레이션 상승한 방출 속도를 나타내는 제어 방출 제제
US20050158382A1 (en) * 2003-09-26 2005-07-21 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
ATE544447T1 (de) 2003-09-26 2012-02-15 Alza Corp Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
CA2874604A1 (en) * 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
CN1938004B (zh) * 2004-03-30 2011-12-21 欧洲凯尔特公司 包含吸附剂和不利剂的抗篡改剂型
EP1584335A3 (de) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Zusammensetzung aus Aktiva mit einer Carbinolverbindung und einem Opioid
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
AU2005329255B2 (en) * 2004-04-15 2010-09-30 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
EP1604667A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung des Restless Leg Syndroms
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
WO2006013431A1 (en) * 2004-07-29 2006-02-09 Pfizer Limited Stable controlled-release pharmaceutical formulation of eletriptan
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
EP1786404A2 (de) 2004-09-01 2007-05-23 Euro-Celtique S.A. Opioid-dosierformen mit steady-state-cave proportional zur dosierung und auc und einzeldosen-cmax geringer als proportional zur dosierung
KR101492361B1 (ko) 2004-09-17 2015-02-11 듀렉트 코퍼레이션 바람직하게 ｓａｉｂ와 같은 당 에스테르를 포함하는 지속적인 국소 마취제 조성물
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
BRPI0517166A (pt) * 2004-12-09 2008-09-30 Celgene Corp uso de d-treo-metilfenidato ou um sal do mesmo
TWI432196B (zh) * 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
CN101132772B (zh) * 2005-01-28 2012-05-09 欧洲凯尔特公司 耐醇剂型
EP1695700A1 (de) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Darreichungsform enthaltend Oxycodon und Naloxon
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
BRPI0613547A2 (pt) 2005-07-20 2011-01-18 Panacea Biotec Ltd forma de dosagem de liberação modificada e respectivo uso
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
BRPI0613943B1 (pt) 2005-07-27 2021-06-22 Otsuka America Pharmaceutical, Inc Composto, composição farmacêutica o compreendendo, usos de um composto e de uma composição farmacêutica, bem como composição neurobiologicamente ativa
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
WO2007025005A2 (en) 2005-08-24 2007-03-01 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
ES2620293T3 (es) 2005-09-09 2017-06-28 Paladin Labs Inc. Composición de liberación sostenida de fármacos
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
US7858609B2 (en) 2005-11-28 2010-12-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
FR2894143B1 (fr) 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
EP1810678A1 (de) * 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2007103557A2 (en) 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
HUE032156T2 (en) 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
WO2008015221A2 (en) * 2006-08-04 2008-02-07 Ethypharm Multilayer orally disintegrating tablet
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2124556B1 (de) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US8298576B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
CA2669815A1 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
AU2007329373B2 (en) * 2006-12-04 2013-06-20 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2167083B1 (de) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexane, verfahren zu ihrer herstellung und ihre verwendung als medikamente
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20080318994A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
US20080318993A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
CA2923102C (en) * 2007-08-13 2019-10-15 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
KR20100069685A (ko) * 2007-10-16 2010-06-24 라보팜 인코포레이트 아세트아미노펜과 트라마돌의 지속 방출을 위한 이중층 조성물
JP2011506318A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 経口医薬製剤
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
BRPI0821732A2 (pt) 2007-12-17 2015-06-16 Labopharm Inc Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CA2720108C (en) 2008-03-11 2016-06-07 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
PT2343982T (pt) 2008-09-17 2017-07-04 Chiasma Inc Composições farmacêuticas e métodos de administração associados
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
EP2367541B1 (de) 2008-12-16 2014-07-16 Paladin Labs Inc. Formulierung mit gesteuerter freisetzung und missbrauchsschutz
AU2009332963B2 (en) 2008-12-31 2015-02-05 Upsher-Smith Laboratories, Llc Opioid-containing oral pharmaceutical compositions and methods
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2011026125A2 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US9023390B2 (en) 2009-09-17 2015-05-05 Upsher-Smith Laboratories, Inc. Sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti-inflammatory drug
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2568977A1 (de) 2010-05-11 2013-03-20 Cima Labs Inc. Alkoholresistente metoprololhaltige orale retard-dosierformen
JP5819680B2 (ja) * 2010-09-03 2015-11-24 帝人ファーマ株式会社 塩酸アンブロキソールの小型徐放性製剤
KR101572336B1 (ko) 2010-12-22 2015-11-26 퍼듀 퍼머 엘피 케이싱된 탬퍼 저항성 제어 방출 투여 형태
CN103327969A (zh) 2010-12-23 2013-09-25 普渡制药公司 抗篡改固体口服剂型
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
AR092820A1 (es) 2012-04-17 2015-05-06 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
WO2014006004A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
PL2872121T3 (pl) 2012-07-12 2019-02-28 SpecGx LLC Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
US10322120B2 (en) 2012-07-31 2019-06-18 Persion Pharmaceuticals Llc Treating pain in patients with hepatic impairment
EA201500742A1 (ru) 2013-02-05 2015-12-30 Пердью Фарма Л.П. Защищенные от нецелевого использования фармацевтические композиции
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP2799009A1 (de) * 2013-04-29 2014-11-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Nichtinvasives Verfahren zur Vorhersage von Opioid-Analgesie und Opioid-Blutkonzentrationen
ES2718211T3 (es) 2013-05-24 2019-06-28 Rhodes Tech Compuestos cetales opioides y usos de los mismos
EP3024461B1 (de) 2013-07-23 2020-05-13 Euro-Celtique S.A. Kombination aus oxycodon und naloxon für die verwendung bei der behandlung von schmerzen bei patienten mit schmerzen und einer krankheit, die zur intestinaldysbiose und/oder erhöhung der gefahr bakterieller translokation führt
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
US9145420B1 (en) 2015-03-27 2015-09-29 Johnson Matthey Public Limited Company Crystalline forms of morphine sulfate
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
DE102016014603A1 (de) 2016-06-30 2018-01-04 Thomas Herkenroth Synthetisches Ayahuasca
AU2017311412B2 (en) 2016-08-11 2023-05-18 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
CN106266068A (zh) * 2016-09-18 2017-01-04 遵义师范学院 一种速释‑缓控释型对坐叶微丸胶囊及其制备方法
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CA3091826A1 (en) 2018-02-23 2019-08-29 Rhodes Technologies Novel opioid compounds and uses thereof
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2806033A (en) * 1955-08-03 1957-09-10 Lewenstein Morphine derivative
IL26896A (en) * 1966-01-19 1970-11-30 Endo Lab 14 - Hydroxynormorphinins and 14 - Hydroxynormorphinones
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3684584A (en) * 1971-03-15 1972-08-15 Driver Co Wilbur B Thermocouple extension wire
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4162753A (en) * 1978-07-13 1979-07-31 Brown William R Necktie hanger
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
DE3024416C2 (de) * 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
US4366159A (en) * 1981-09-08 1982-12-28 Michael Richard Magruder Nalbuphine-narcotic analgesic composition and method of producing analgesia
DE3208791A1 (de) * 1982-03-11 1983-09-22 Röhm GmbH, 6100 Darmstadt Verfahren zum ueberziehen von arzneiformen mittes eines in wasser dispergierten ueberzugsmittels
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
ZA836627B (en) * 1982-10-08 1984-05-30 Verex Lab Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility
US4466646A (en) * 1983-02-25 1984-08-21 General Motors Corporation Energy absorbing bumper assembly for vehicles
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
EP0147780A3 (de) * 1984-01-03 1987-03-11 Merck & Co. Inc. Vorrichtung zur Freisetzung von Arzneistoffen
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4894234A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for antiarrhythmics
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
US4569937A (en) * 1985-02-11 1986-02-11 E. I. Du Pont De Nemours And Company Analgesic mixture of oxycodone and ibuprofen
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
EP0204951B1 (de) * 1985-05-13 1993-01-20 Miles Inc. Verwendung von Kalziumantagonisten zur Anfertigung von Zusammensetzungen für Entziehungssymptome
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
GB2186485B (en) * 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ATE107857T1 (de) * 1986-06-10 1994-07-15 Euro Celtique Sa Zusammensetzung mit kontrollierter freisetzung von dihydrocodein.
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
JP2643222B2 (ja) † 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
JP2681373B2 (ja) * 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法
US4983730A (en) * 1988-09-02 1991-01-08 Hoechst Celanese Corporation Water soluble cellulose acetate composition having improved processability and tensile properties
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DK161743C (da) * 1989-07-03 1992-02-17 Niro Atomizer As Fremgangsmaade og apparat til agglomerering af et pulverformigt materiale
JPH03163030A (ja) * 1989-08-28 1991-07-15 Arizona Technol Dev Corp アヘン剤活性を選択的に強化し、アヘン剤耐性と依存性を軽減するための組成物と方法
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5198203A (en) * 1990-01-25 1993-03-30 Mobil Oil Corp. Synthetic mesoporous crystalline material
WO1992001446A1 (en) * 1990-07-20 1992-02-06 Aps Research Limited Sustained-release formulations
ES2075403T3 (es) * 1990-08-24 1995-10-01 Spirig Ag Pharmazeutische Prap Procedimiento para la fabricacion de pellets.
SE9003296L (sv) * 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5132142A (en) * 1991-03-19 1992-07-21 Glatt Gmbh Apparatus and method for producing pellets by layering power onto particles
ATE159426T1 (de) * 1991-04-16 1997-11-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer festen dispersion
MY110317A (en) * 1991-09-06 1998-04-30 Mcneilab Inc Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone, and their use.
HU219332B (hu) * 1991-09-06 2001-03-28 Mcneilab Inc Transz-(+)-2-[(dimetil-amino)-metil]-1-(3-metoxi-fenil)-ciklohexanolt és acetaminofent tartalmazó szinergetikus gyógyszerkészítmények
US5223541A (en) * 1991-09-13 1993-06-29 Mcneilab, Inc. Tramadol n-oxide material, enantiomers and compositions thereof, and their use
US5226331A (en) * 1991-10-03 1993-07-13 General Electric Company Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream
GB9121204D0 (en) * 1991-10-04 1991-11-20 Euro Celtique Sa Medicament
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) † 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
SE9200858L (sv) * 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
ATE223704T1 (de) * 1992-10-16 2002-09-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung von wachsmatrizes
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
DE69425453T2 (de) * 1993-04-23 2001-04-12 Novartis Ag Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
DE4315525B4 (de) † 1993-05-10 2010-04-15 Euro-Celtique S.A. Pharmazeutische Zusammensetzung
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL109944A (en) * 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5358269A (en) * 1993-08-30 1994-10-25 Jakeman Walter L Trailer hitch
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
EP2036558A3 (de) * 1993-10-07 2010-04-28 Euro-Celtique S.A. Oral anzuwendende opioidhaltige Zusammensetzungen mit verlängerter Wirkung
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
FR2729857B1 (fr) * 1995-01-27 1997-04-04 Rhone Poulenc Chimie Compositions pharmaceutiques sous forme de comprimes a liberation prolongee a base de granules en polysaccharides de haut poids moleculaire
US5716631A (en) * 1995-09-29 1998-02-10 Rdn Therapeutics Inc. Long acting narcotic analgesics and antagonists
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
JP4083818B2 (ja) * 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
US6391336B1 (en) * 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6085954A (en) * 1998-07-15 2000-07-11 Graber Products, Inc. Pivoting extensible rear hitch attachment for equipment carrier
KR20000011247A (ko) * 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
US6736434B2 (en) * 2000-03-22 2004-05-18 Meridian Automotive Systems, Inc. Vehicle and bumper assembly therefor having an integral fascia and energy absorber, and method for making the same
US9820982B2 (en) * 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US20030129234A1 (en) * 2001-07-06 2003-07-10 Penwest Pharmaceuticals Company Methods of making sustained release formulations of oxymorphone
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse

Also Published As

Publication number Publication date
AU1331395A (en) 1995-06-13
EP0731694B2 (de) 2005-09-07
EP1023896A2 (de) 2000-08-02
JPH09505602A (ja) 1997-06-03
DK1023896T3 (da) 2007-05-14
NZ277917A (en) 1998-04-27
NO954925L (no) 1996-05-23
NO315147B1 (no) 2003-07-21
EP0731694B1 (de) 2002-02-06
CZ321795A3 (en) 1996-07-17
EP1776950A1 (de) 2007-04-25
DE69434911D1 (de) 2007-02-15
CN1130352A (zh) 1996-09-04
EP1023896A9 (de) 2007-05-23
KR960703004A (ko) 1996-06-19
PT1023896E (pt) 2007-03-30
US20080031963A1 (en) 2008-02-07
DK0731694T3 (da) 2002-05-13
KR100201767B1 (ko) 1999-06-15
US20020058050A1 (en) 2002-05-16
US20070237833A1 (en) 2007-10-11
DE69429826D1 (de) 2002-03-21
PT731694E (pt) 2002-06-28
IL111742A (en) 2004-02-19
EP1023896A3 (de) 2003-05-02
ES2170136T3 (es) 2002-08-01
ES2266951T3 (es) 2007-03-01
JP2006290901A (ja) 2006-10-26
US20100209351A1 (en) 2010-08-19
DE69434911T2 (de) 2007-08-30
BG100346A (bg) 1996-07-31
AU693134B2 (en) 1998-06-25
EP1023896B1 (de) 2007-01-03
JP4368562B2 (ja) 2009-11-18
BG63269B1 (bg) 2001-08-31
JP2004323536A (ja) 2004-11-18
JP2009102376A (ja) 2009-05-14
HU9503468D0 (en) 1996-01-29
CN1134253C (zh) 2004-01-14
EP1470815A1 (de) 2004-10-27
US20070237832A1 (en) 2007-10-11
ES2279742T3 (es) 2007-09-01
SK283544B6 (sk) 2003-09-11
HUT73976A (en) 1996-10-28
PL312587A1 (en) 1996-04-29
DK0731694T4 (da) 2005-12-19
TW420617B (en) 2001-02-01
NZ508526A (en) 2004-12-24
JP4908527B2 (ja) 2012-04-04
ES2170136T5 (es) 2006-04-01
FI955782A (fi) 1996-01-30
PT1470815E (pt) 2006-09-29
NO954925D0 (no) 1995-12-05
HK1029927A1 (en) 2001-04-20
DE69429826T3 (de) 2006-08-03
NZ336055A (en) 2001-01-26
EP0731694A1 (de) 1996-09-18
SK153895A3 (en) 1996-06-05
JP2002371015A (ja) 2002-12-26
DK1470815T3 (da) 2006-10-02
JP4425093B2 (ja) 2010-03-03
US5672360A (en) 1997-09-30
ATE327739T1 (de) 2006-06-15
DE69429826T2 (de) 2002-09-05
US20030035837A1 (en) 2003-02-20
FI955782A0 (fi) 1995-12-01
US20100209514A1 (en) 2010-08-19
CZ292936B6 (cs) 2004-01-14
ATE350022T1 (de) 2007-01-15
US20060269604A1 (en) 2006-11-30
WO1995014460A1 (en) 1995-06-01
IL111742A0 (en) 1995-01-24
EP1470815B1 (de) 2006-05-31
US5478577A (en) 1995-12-26
FI121588B (fi) 2011-01-31
JP4767772B2 (ja) 2011-09-07
EP0731694A4 (de) 1996-10-02
ATE212831T1 (de) 2002-02-15
DE69434752T2 (de) 2007-05-16

Similar Documents

Publication Publication Date Title
ATE212831T1 (de) Opioid-formulierungen zur schmerzbehandlung
AUPN603895A0 (en) Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
WO1998036728A3 (en) Sustained analgesia achieved with buprenorphine
DE60138547D1 (de) Topisch anwendbare arzneipräparate und verfahren zur behandlung
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
PT904067E (pt) Dextrometorfan como agente antitussico administrado transdermicamente
US6280766B1 (en) Method for transdermal application of active substances at high constant dosage
WO2002047688A3 (en) Method and apparatus for treating breakthrough pain
HUP9900521A2 (hu) Eljárás nagyon kis dózisú hatóanyagok szilárd dózisformáinak előállítására
SE9101341D0 (sv) New medicinal use
WO2001041771A3 (de) Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne
UA30654A (uk) Спосіб лікування посттравматичних дисфункцій висково- нижньощелепового суглоба
IL164092A0 (en) The use of devazepide as analgesic agent
UA5715C2 (uk) Спосіб індивідуального підбору оптимальних доз судинорозширюючих препаратів та пристрій для його здійснення
UA30631A (uk) Спосіб лікування надмірної ваги

Legal Events

Date Code Title Description
8364 No opposition during term of opposition